Abstract

Cranial electrotherapy stimulation (CES) is a neuromodulation tool used for treating several clinical disorders, including insomnia, anxiety, and depression. More recently, a limited number of studies have examined CES for altering affect, physiology, and behavior in healthy, non-clinical samples. The physiological, neurochemical, and metabolic mechanisms underlying CES effects are currently unknown. Computational modeling suggests that electrical current administered with CES at the earlobes can reach cortical and subcortical regions at very low intensities associated with subthreshold neuromodulatory effects, and studies using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) show some effects on alpha band EEG activity, and modulation of the default mode network during CES administration. One theory suggests that CES modulates brain stem (e.g., medulla), limbic (e.g., thalamus, amygdala), and cortical (e.g., prefrontal cortex) regions and increases relative parasympathetic to sympathetic drive in the autonomic nervous system. There is no direct evidence supporting this theory, but one of its assumptions is that CES may induce its effects by stimulating afferent projections of the vagus nerve, which provides parasympathetic signals to the cardiorespiratory and digestive systems. In our critical review of studies using CES in clinical and non-clinical populations, we found severe methodological concerns, including potential conflicts of interest, risk of methodological and analytic biases, issues with sham credibility, lack of blinding, and a severe heterogeneity of CES parameters selected and employed across scientists, laboratories, institutions, and studies. These limitations make it difficult to derive consistent or compelling insights from the extant literature, tempering enthusiasm for CES and its potential to alter nervous system activity or behavior in meaningful or reliable ways. The lack of compelling evidence also motivates well-designed and relatively high-powered experiments to assess how CES might modulate the physiological, affective, and cognitive responses to stress. Establishing reliable empirical links between CES administration and human performance is critical for supporting its prospective use during occupational training, operations, or recovery, ensuring reliability and robustness of effects, characterizing if, when, and in whom such effects might arise, and ensuring that any benefits of CES outweigh the risks of adverse events.

Highlights

  • A BRIEF HISTORY OF CESCranial electrotherapy stimulation (CES)Cranial electrotherapy stimulation (CES) involves delivering low-intensity (50 μA to 4 mA) electrical current via a pair of electrodes attached to bilateral anatomical positions around the head, with the intent of acutely modulating central and/or peripheral nervous system activity

  • CES was developed as a tool for treating the symptoms of clinical disorders such as insomnia, anxiety, and depression

  • The Food and Drug Administration (FDA) differently regulates CES devices based on their intent, with relatively stringent controls (Class III) for the treatment of depression, given a lack of data demonstrating that any benefits outweigh potential risks

Read more

Summary

A BRIEF HISTORY OF CES

Cranial electrotherapy stimulation (CES) involves delivering low-intensity (50 μA to 4 mA) electrical current via a pair of electrodes attached to bilateral anatomical positions around the head (e.g., eyelids, earlobes, mastoids, temples), with the intent of acutely modulating central and/or peripheral nervous system activity. An emergency first responder might incorporate neuromodulatory techniques to accelerate the learning of new procedural skills, modulate stress responses during high-stakes operations, or to assist emotion regulatory processes following exposure to stress In these scenarios, CES may carry potential to help sustain or improve behavioral outcomes related to occupational performance including vigilance, perceptuomotor control, situation awareness, and emotion regulation. The United States Food and Drug Administration (FDA) classifies medical devices into three Classes: Class I, II, and III, each with their own regulatory controls (Peña et al, 2007). CES devices marketed to treat depression are classified as Class III medical devices, requiring additional regulatory oversight due to potential unreasonable risk of illness or injury (21CFR860.3).

Alpha-Stim
Findings
CONCLUSIONS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.